Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting

Translational Research

Volumn 164, Issue 2, 2014, Pages 169-176

  Lu, Chien Yu ^a,b   Huang, Ching Wen ^a,b,c   Hu, Huang Ming ^a,b   Tsai, Hsiang Lin ^a   Huang, Chun Ming ^a,b   Yu, Fang Jung ^a,b   Huang, Ming Yii ^a,b   Chang, Se Fen ^a   Huang, Meng Lin ^d,e   Wang, Jaw Yuan ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d ZUOYING ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

5 fluorouracil; 5 fluorouracil leucovorin with irinotecan; 5 FU; 7 ethyl 10 hydroxycamptothecin; Abbreviations; adverse event; AE; colorectal cancer; CRC; FOLFIRI; intravenous; IV; leucovorin; LV; mCRC; metastatic colorectal cancer; OS; overall survival; PCR; PFS; polymerase chain reaction; progression free survival; SN 38; UGT1A1; uridine diphosphate glucuronosyltransferase 1A1

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CONTROL GROUP; DRUG DOSE ESCALATION; DRUG RESPONSE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PROGNOSIS; VITAMIN B COMPLEX;

EID: 84904814707     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2013.12.009     Document Type: Article

References (34)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. D. Arnold, and A. Stein New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy Drugs 73 2013 883 891
3. T.H. Cartwright Treatment decisions after diagnosis of metastatic colorectal cancer Clin Colorectal Cancer 11 2012 155 166
4. M. Saunders, and T. Iveson Management of advanced colorectal cancer: state of the art Br J Cancer 95 2006 131 138 (Pubitemid 44050911)
5. P. Thirion, S. Michiels, and J.P. Pignon et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis J Clin Oncol 22 2004 3766 3775
6. B.H. O'Neil, and R.M. Goldberg Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials Oncologist 13 2008 1074 1083
7. L.B. Saltz, J.V. Cox, and C. Blanke et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group N Engl J Med 343 2000 905 914
8. J.Y. Douillard, D. Cunningham, and A.D. Roth et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047 (Pubitemid 30162806)
9. J.O. Miners, R.A. McKinnon, and P.I. Mackenzie Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance Toxicology 181-182 2002 453 456 (Pubitemid 36015736)
10. R.H. Mathijssen, R.J. van Alphen, and J. Verweij et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin Cancer Res 7 2001 2182 2194 (Pubitemid 32751614)
11. L. Iyer, C.D. King, and P.F. Whitington et al. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J Clin Invest 101 1998 847 854 (Pubitemid 28096082)
12. G. Monaghan, M. Ryan, R. Seddon, R. Hume, and B. Burchell Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome Lancet 347 1996 578 581 (Pubitemid 26070740)
13. E. Marcuello, D. Paez, and L. Pare et al. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer Br J Cancer 105 2011 53 57
14. G. Toffoli, E. Cecchin, and G. Gasparini et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer J Clin Oncol 28 2010 866 871
15. G.E. Palomaki, L.A. Bradley, M.P. Douglas, K. Kolor, and W.D. Dotson Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review Genet Med 11 2009 21 34
16. M. Hebbar, M. Ychou, and M. Ducreux Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer J Cancer Res Clin Oncol 135 2009 749 752
17. H.-L. Tsai, C.-F. Chen, and C.-Y. Lu et al. Significant correlation between polymorphisms of UGT1A1 gene and low irinotecan toxicity in colorectal cancer patients with FOLFIRI Open Colorectal Cancer J 2 2009 21 26
18. H. Hurwitz, L. Fehrenbacher, and W. Novotny et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
19. E. Van Cutsem, C.H. Kohne, and E. Hitre et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
20. M. Peeters, and T. Price Biologic therapies in the metastatic colorectal cancer treatment continuum: applying current evidence to clinical practice Cancer Treat Rev 38 2012 397 406
21. Primer3web version 4.0.0. Available at: http://primer3.ut.ee/. Accessed January 2014.
22. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
23. M.-L. Huang, J.-Y. Kan, and C.-J. Ma et al. An observational study of bevacizumab combined with FOLFIRI as the first-line treatment in metastatic colorectal cancer Genom Med Biomarkers Health Sci 4 2012 122 127
24. H.L. McLeod, D.J. Sargent, and S. Marsh et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741 J Clin Oncol 28 2010 3227 3233
25. L.T. Macedo, A.B. da Costa Lima, and A.D. Sasse Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups BMC Cancer 12 2012 89
26. A. Okines, O.D. Puerto, and D. Cunningham et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial Br J Cancer 101 2009 1033 1038
27. J. Figueras, S. Lopez-Ben, and M. Alsina et al. Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma Clin Transl Oncol 15 2013 460 466
28. G. Bruera, K. Cannita, and F. Giuliante et al. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab Clin Colorectal Cancer 11 2012 119 126
29. Z.Y. Hu, Q. Yu, and Y.S. Zhao Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis Eur J Cancer 46 2010 1856 1865
30. Z.Y. Hu, Q. Yu, Q. Pei, and C. Guo Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk Clin Cancer Res 16 2010 3832 3842
31. J.M. Hoskins, R.M. Goldberg, P. Qu, J.G. Ibrahim, and H.L. McLeod UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters J Natl Cancer Inst 99 2007 1290 1295 (Pubitemid 47394168)
32. P.J. O'Dwyer, and R.B. Catalano Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy J Clin Oncol 24 2006 4534 4538 (Pubitemid 46630947)
33. A.O. Berg, K. Armstrong, and J. Botkin et al. Recommendations from the EGAPP working group, can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med 11 2009 15 20
34. K. Shulman, I. Cohen, and O. Barnett-Griness et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients Cancer 117 2011 3156 3162